TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses.
Int J Gynecol Cancer. 2019 Jan 18;:
Blood Adv. 2018 Dec 11;2(23):3506-3514
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Eur J Cancer. 2018 Dec 06;107:1-7
J Autoimmun. 2018 Oct 11;:
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
Br J Cancer. 2018 Sep 11;:
A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium.
Clin Cancer Res. 2018 Aug 14;:
Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
Melanoma Res. 2018 Jul 31;:
Cancer Immunol Res. 2018 Jul 17;:
Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective.
Obstet Gynecol Int. 2018;2018:1867238
DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.
Nat Commun. 2018 May 15;9(1):1915